» Articles » PMID: 26257296

Identification of Discrete Prognostic Groups in Ewing Sarcoma

Overview
Date 2015 Aug 11
PMID 26257296
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although multiple prognostic variables have been proposed for Ewing sarcoma (EWS), little work has been done to further categorize these variables into prognostic groups for risk classification.

Procedure: We derived initial prognostic groups from 2,124 patients with EWS in the SEER database. We constructed a multivariable recursive partitioning model of overall survival using the following covariates: age; stage; race/ethnicity; sex; axial primary; pelvic primary; and bone or soft tissue primary. Based on this model, we identified risk groups and estimated 5-year overall survival for each group using Kaplan-Meier methods. We then applied these groups to 1,680 patients enrolled on COG clinical trials.

Results: A multivariable model identified five prognostic groups with significantly different overall survival: (i) localized, age <18 years, non-pelvic primary; (ii) localized, age <18, pelvic primary or localized, age ≥18, white, non-Hispanic; (iii) localized, age ≥18, all races/ethnicities other than white, non-Hispanic; (iv) metastatic, age <18; and (v) metastatic, age ≥18. These five groups were applied to the COG dataset and showed significantly different overall and event-free survival based upon this classification system (P < 0.0001). A sub-analysis of COG patients treated with ifosfamide and etoposide as a component of therapy evaluated these findings in patients receiving contemporary therapy.

Conclusions: Recursive partitioning analysis yields discrete prognostic groups in EWS that provide valuable information for patients and clinicians in determining an individual patient's risk of death. These groups may enable future clinical trials to adjust EWS treatment according to individualized risk.

Citing Articles

Molecular characterization informs prognosis in patients with localized Ewing sarcoma: A report from the Children's Oncology Group.

Gillani R, Shulman D, DelRocco N, Klega K, Han R, Krailo M medRxiv. 2025; .

PMID: 39974064 PMC: 11838998. DOI: 10.1101/2025.01.20.25320840.


Long-term follow-up results of pediatric and adolescent patients with localized Ewing sarcoma treated based on stratified modalities.

Zeng C, Chen T, Wang J, Sun F, Huang J, Lu S Cancer Med. 2023; 12(8):9409-9419.

PMID: 36808251 PMC: 10166922. DOI: 10.1002/cam4.5703.


Adverse prognostic impact of the loss of STAG2 protein expression in patients with newly diagnosed localised Ewing sarcoma: A report from the Children's Oncology Group.

Shulman D, Chen S, Hall D, Nag A, Thorner A, Lessnick S Br J Cancer. 2022; 127(12):2220-2226.

PMID: 36221002 PMC: 9726932. DOI: 10.1038/s41416-022-01977-2.


An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma.

Shulman D, Whittle S, Surdez D, Bailey K, de Alava E, Yustein J NPJ Precis Oncol. 2022; 6(1):65.

PMID: 36115869 PMC: 9482616. DOI: 10.1038/s41698-022-00307-2.


Derivation and validation of a risk classification tree for patients with synovial sarcoma.

Neel D, Ma C, Collins N, Hornick J, Demetri G, Shulman D Cancer Med. 2022; 12(1):170-178.

PMID: 35670308 PMC: 9844650. DOI: 10.1002/cam4.4909.


References
1.
Baldini E, Demetri G, Fletcher C, Foran J, Marcus K, Singer S . Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome. Ann Surg. 1999; 230(1):79-86. PMC: 1420848. DOI: 10.1097/00000658-199907000-00012. View

2.
Bacci G, Balladelli A, Forni C, Ferrari S, Longhi A, Bacchini P . Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60: report of 35 cases and comparison of results with 586 younger patients treated with the same protocols in the same years. Cancer. 2007; 109(4):780-6. DOI: 10.1002/cncr.22456. View

3.
Felgenhauer J, Nieder M, Krailo M, Bernstein M, Henry D, Malkin D . A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893. Pediatr Blood Cancer. 2012; 60(3):409-14. PMC: 4583823. DOI: 10.1002/pbc.24328. View

4.
Karski E, Matthay K, Neuhaus J, Goldsby R, Dubois S . Characteristics and outcomes of patients with Ewing sarcoma over 40 years of age at diagnosis. Cancer Epidemiol. 2012; 37(1):29-33. PMC: 3543501. DOI: 10.1016/j.canep.2012.08.006. View

5.
Meyers P, Krailo M, Ladanyi M, Chan K, Sailer S, Dickman P . High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol. 2001; 19(11):2812-20. DOI: 10.1200/JCO.2001.19.11.2812. View